BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gergoudis SC, DeFilipp Z, Özbek U, Sandhu KS, Etra AM, Choe HK, Kitko CL, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner EO, Hogan WJ, Holler E, Kasikis S, Kowalyk SM, Lin JY, Merli P, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen YB, Ferrara JLM, Levine JE. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin. Blood Adv 2020;4:6098-105. [PMID: 33351103 DOI: 10.1182/bloodadvances.2020003336] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Neidemire-colley L, Robert J, Ackaoui A, Dorrance AM, Guimond M, Ranganathan P. Role of endothelial cells in graft-versus-host disease. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1033490] [Reference Citation Analysis]
2 Bidgoli A, Depriest BP, Saatloo MV, Jiang H, Fu D, Paczesny S. Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.07.008] [Reference Citation Analysis]
3 Etra A, Gergoudis S, Morales G, Spyrou N, Shah J, Kowalyk S, Ayuk F, Baez J, Chanswangphuwana C, Chen YB, Choe H, DeFilipp Z, Gandhi I, Hexner E, Hogan WJ, Holler E, Kapoor U, Kitko CL, Kraus S, Lin JY, Al Malki M, Merli P, Pawarode A, Pulsipher MA, Qayed M, Reshef R, Rösler W, Schechter T, Van Hyfte G, Weber D, Wölfl M, Young R, Özbek U, Ferrara JLM, Levine JE. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Adv 2022;6:3707-15. [PMID: 35443021 DOI: 10.1182/bloodadvances.2022007296] [Reference Citation Analysis]
4 Song Q, Nasri U, Zeng D. Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model. Front Immunol 2022;13:844271. [DOI: 10.3389/fimmu.2022.844271] [Reference Citation Analysis]
5 Rayasam A, Drobyski WR. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease. Front Immunol 2021;12:779076. [PMID: 34899738 DOI: 10.3389/fimmu.2021.779076] [Reference Citation Analysis]
6 Kaviany S, Kitko CL. The role of biomarkers in risk stratification, treatment and outcome in acute GVHD. Curr Opin Hematol 2021;28:401-7. [PMID: 34475350 DOI: 10.1097/MOH.0000000000000681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Choe H, Ferrara JLM. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opin Ther Targets 2021;25:761-71. [PMID: 34669521 DOI: 10.1080/14728222.2021.1992383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Khanolkar RA, Kalra A, Kinzel M, Pratt LM, Dharmani-Khan P, Chaudhry A, Williamson TS, Daly A, Morris DG, Khan FM, Storek J. A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. Cytotherapy 2021:S1465-3249(21)00711-8. [PMID: 34373186 DOI: 10.1016/j.jcyt.2021.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers ME, Cutler C, Jagasia M, Gooley T, Palmer J, Randolph T, Levine JE, Ayuk F, Dignan F, Schoemans H, Tkaczyk E, Farhadfar N, Lawitschka A, Schultz KR, Martin PJ, Sarantopoulos S, Inamoto Y, Socie G, Wolff D, Blazar B, Greinix H, Paczesny S, Pavletic S, Hill G. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther 2021;27:632-41. [PMID: 33836313 DOI: 10.1016/j.jtct.2021.03.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]